Description

Phenibut HCL Powder

Phenibut HCL
CAS Number	1078-21-3
Molar Mass	179.219 g·mol−1
Chemical Formula	C10H13NO2
IUPAC Name	4-Amino-3-phenylbutanoic acid

Introduction

Phenibut HCL (Hydrochloride) Powder is a research compound known for its potential applications in anxiety research, cognitive enhancement studies, and investigations into chronic fatigue. It is crucial to emphasize that this product is strictly intended for research purposes, and any mention of human consumption is strictly prohibited.

Key Characteristics

Phenibut HCL is a modified form of phenibut, incorporating hydrochloride for enhanced solubility. As a derivative of GABA, it interacts with GABA receptors in the brain, influencing neurotransmission and potentially demonstrating various effects.

Research Applications

Researchers explore the applications of Phenibut HCL in various scientific domains, including neuroscience, psychology, and fatigue-related studies. Its unique pharmacological profile makes it a subject of interest for investigators examining anxiety, cognitive function, and fatigue mechanisms.

Research Benefits

Phenibut and Anxiety

Phenibut HCL’s potential anxiolytic properties make it a focal point in anxiety research. Studies investigate its impact on GABAergic neurotransmission and its potential role in modulating anxiety-related behaviors.

Phenibut and Cognitive Enhancement

Research suggests that Phenibut HCL may influence cognitive function, particularly in terms of memory and attention. Investigations explore its mechanisms of action and potential applications in cognitive enhancement studies.

Phenibut and Chronic Fatigue

Phenibut HCL’s impact on chronic fatigue is a subject of interest in fatigue research. Preliminary studies indicate its potential role in modulating fatigue-related processes, providing insights into its utility in combating fatigue.

Summary

Phenibut HCL Powder exhibits potential benefits in anxiety modulation, cognitive enhancement, and fatigue research. As a research tool, its distinct pharmacological profile contributes to our understanding of GABAergic neurotransmission and related physiological processes.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Shypilova EM, Zavadenko NN, Nesterovskiy YE. Profilakticheskaia terapiia golovnoĭ boli napriazheniia u deteĭ i podrostkov [Preventive treatment of tension headache in children and adolescents]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(7):36-42. Russian. doi: 10.17116/jnevro20171177136-42. PMID: 28805758. [Read More].
2. Chutko LS, Surushkina SIu, Iakovenko EA, Nikishena IS, Anisimova TI, Bondarchuk IuL. [Cognitive and emotional impairments in patients with protracted anxiety-phobic disorders]. Ter Arkh. 2014;86(12):61-5. Russian. doi: 10.17116/terarkh2014861261-65. PMID: 25804042. [Read More].
3. Vorob’eva OV, Rusaya VV. Éffektivnost’ i bezopasnost’ preparata noofen v terapii sindroma khronicheskoĭ ustalosti u bol’nykh s tserebrovaskuliarnoĭ nedostatochnost’iu [Efficacy and safety of noophen in the treatment of chronic fatigue syndrome in patients with cerebrovascular insufficiency]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(11):31-36. Russian. doi: 10.17116/jnevro201711711131-36. PMID: 29265084. [Read More].